Table 3.

Summary of Phase III Clinical Trials Using Anti-VEGF Agents for Myopic Choroidal Neovascularization

Study	Treatment Groups	No. of Eyes	Mean BCVA Change at Study Primary End Point	Mean BCVA Change at Study Final Visit	Mean No. of Anti-VEGF Injections Over Study Period
RADIANCE158	Ranibizumab 0.5 mg guided by BCVA stabilization	106	+10.5 letters at month 3	+13.8 letters at month 12 month	4.6 ranibizumab injections over 12 months
	Ranibizumab 0.5 mg guided by disease activity	116	+10.6 letters at month 3	+14.4 letters at month 12 month	3.5 ranibizumab injections over 12 months
	vPDT then eligible to add ranibizumab 0.5 mg after month 3	55	+2.2 letters at month 3	+9.3 letters at month 12	2.4 ranibizumab injections from month 3 to 12
BRILLANCE 160	Ranibizumab 0.5 mg guided by visual stabilization	182	+9.5 letters at month 3	+12.0 letters at month 12	4.6 ranibizumab injections over 12 months
	Ranibizumab 0.5 mg guided by disease activity	184	+9.8 letters at month 3	+13.1 letters at month 12	3.0 ranibizumab injections over 12 months
	vPDT then eligible to add ranibizumab after month 3	91	+4.5 letters at month 3	+10.3 letters at month 12	3.2 ranibizumab injections from month 3 to 12
MYRROR161	Aflibercept 2 mg	91	+12.1 letters at week 24	+13.5 letters at week 48	4.2 aflibercept injections over 48 weeks
	Sham followed by aflibercept 2 mg after week 24	31	–2.0 letters at week 24	+3.9 letters at week 48	3.0 aflibercept injections from week 24 to 48
SHINY162	Conbercept 0.5 mg	132	+12.0 letters at month 3	+13.3 letters at month 9	4.8 conbercept injections over 9 months
	Sham followed by conbercept 0.5 mg after month 3	44	+0.6 letters at month 3	+11.3 letters at month 9	3.6 conbercept injections from month 3 to 9

BCVA, best-corrected visual acuity.